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The human immunodeficiency virus (HIV) envelope glycoprotein forms trimers on the virion surface, with each monomer consisting of
two subunits, gp120 and gp41. The gp120 envelope component binds to CD4 on target cells and undergoes conformational changes that
allow gp120 to interact with certain G-protein-coupled receptors (GPCRs) on the same target membranes. The GPCRs that function as HIV
coreceptors were found to be chemokine receptors. The primary coreceptors are CCR5 and CXCR4, but several other chemokine receptors
were identified as ‘‘minor coreceptors’’, indicating their ability support entry of some HIV strains in tissue cultures. Formation of the tri-
molecular complexes stabilizes virus binding and triggers a series of conformational changes in gp41 that facilitate membrane fusion and
viral cell entry. Concerted efforts are underway to decipher the specific interactions between gp120/CD4, gp120/coreceptors, and their
contributions to the subsequent membrane fusion process. It is hoped that some of the transient conformational intermediates in gp120 and
gp41 would serve as targets for entry inhibitors. In addition, the CD4 and coreceptors are primary targets for several classes of inhibitors
currently under testing. Our review summarizes the current knowledge on the interactions of HIV gp120 with its receptor and coreceptors,
and the important properties of the chemokine receptors and their regulation in primary target cells. We also summarize the classes of
coreceptor inhibitors under development.D 2003 Elsevier B.V. All rights reserved.Keywords: HIV envelope; HIV receptor/coreceptor; Viral-cell fusion; Entry-inhibitor1. Introduction
Within a year after human immunodeficiency virus
(HIV)-1 was discovered as the causative agent for acquired
immunodeficiency syndrome (AIDS), CD4 was shown to be
the receptor for HIV-1 [1,2]. However, because not all CD4-
positive cells allowed entry of HIV-1, the existence of a
second receptor was postulated. The identification of a
second fusion cofactor was accomplished in 1996 by Feng
et al. [3]. This coreceptor turned out to be the receptor for
the CXC chemokine SDF-1 a and was subsequently termed
CXCR4. While CXCR4 functioned with HIV-1 isolates that0005-2736/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0005-2736(03)00162-7
Abbreviations: CD4bs, CD4-binding site; CD4i, CD4-induced; ECI,
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antibody
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lines, it did not function with many primary isolates. Hints
that another chemokine receptor may function for these
viruses came from the work of Cocchi et al. [4], who
demonstrated that the CC chemokines RANTES, MIP-1a,
and MIP-1h could inhibit certain primary and macrophage-
tropic isolates. The chemokine receptor CCR5 was identi-
fied as the fusion cofactor for many primary isolates and
macrophage-tropic viruses [5–9]. Subsequent work has
revealed that between 10 and 20 G-protein-coupled recep-
tors (GPCRs) can function as coreceptors for HIV-1, HIV-2,
and/or simian immunodeficiency virus (SIV), although as
yet there are no data supporting a role for these alternative
or minor coreceptors in vivo [10]. Therefore, CCR5 and
CXCR4 are considered the major HIV coreceptors; CD4 is
now termed the primary receptor, as this molecule is where
the initial contact is made between the virus envelope
surface (SU) component, gp120, and the cell.
With the determination that the major determinant of
viral tropism is the envelope gene and major restriction of
viral infectivity is at the level of entry, a simplified nomen-
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uses CCR5 for entry is termed R5, one that uses CXCR4 for
entry is termed X4, and one that uses both is classified as
R5X4. While this classification system is useful, use of
coreceptor alone does not explain viral tropism, as not all
R5 viruses are able to use CCR5 on macrophages for a
productive infection.Table 1
Summary of coreceptor domain interactions with gp120 and viral fusion
Coreceptor Virus CD4-
dependent
Contributing domains/
amino acids
References
CCR5 HIV-1 + Cytoplasmic tail not
required
[17,122–129]
Amino terminal: aa
1–13; YDINYY motif;
D2, Y3, Y10, D11, I12;
N13; Y14, Y15, S17,
E18, Q21, K22
ECII: G163R#; S184D#;
K197
ECIII: D276; Q280A#
 Amino terminal; ECII [130]
HIV-2 + Amino terminal, ECII [131]
 Amino terminal:
N13Dz; ECII essential
[132]
SIV + Amino terminal: Y10,
D11, Y14,
[128]
 Amino terminal:
N13Dz;
[127,133,134]
CXCR4 HIV-1 + Amino terminal:
YDE-rich cluster,
E15A#; E32A#; Y21A#;
E26A#
[17,18,135–139]
ECI: D97A#
ECII: D193S#; R183A#;
Y184A#; D187A#;
R188A#; Y190A#;
Q200A#
ECIII: E268A#; Q272A#
N-linked glycosylation
(in N-terminal, ECII):
not required
 [140]
HIV-2 +
 Amino terminal:
involved, ECII:
involved
[131,132,141]2. CD4/gp120 interactions
The resolution of the crystal structure of the gp120
‘‘core’’ in association with sCD4 (domains 1 and 2) and
the F(ab) fragment of mAb 17b (directed against a CD4-
induced epitope on gp120) provided detailed information on
the molecular interactions between the virus SU envelope
and its primary receptor, CD4. In addition, it shed light on
the coreceptor-binding site on gp120, which normally
becomes exposed subsequent to CD4/gp120 association
[12,13]. It was established that CD4 is bound to a pocket
in the gp120. Direct interatomic contacts are made between
22 CD4 residues and 26 gp120 residues. These include 219
van der Waals contacts and 12 hydrogen bonds. Importantly,
Phe 43 and Arg 59 of CD4 were shown to make multiple
contacts centered on residues Asp 368, Glu 370, and Trp
427 of gp120, which are all conserved among primate
immunodeficiency viruses. The Phe 43 cavity is roughly
spherical, with a diameter of about 8 A˚. The phenyl ring of
Phe 43 is the only non-gp120 residue contacting this cavity
[13]. The gp120–CD4 interface includes two cavities, one
water-filled and bounded equally by both proteins, and the
other extending into gp120 interior and contacting CD4
only at Phe 43 [12]. The Phe 43 cavity is surrounded by a
gp120 ‘‘ridge’’ containing amino acids Asp 368 and Glu
370, previously shown to be part of the neutralizing epitopes
in the CD4 binding site [14]. Residues that line the Phe 43
cavity (Trp 112, Val 255, Thr 257, Glu 370, Phe 382, Tyr
384, Trp 427, and Met 475) are primarily hydrophobic.
They are also highly conserved, as much as the buried
gp120 hydrophobic core. Despite the lack of steric hin-
drance, almost no substitutions were identified in these
residues, implying functional significance. While these
residues do not have direct contact with CD4, they do affect
gp120–CD4 interactions. Mutation of Thr 257 and Trp 427
can substantially reduce CD4 binding. Furthermore, muta-
tion of these residues was found to reduce the binding of
antibodies against the CD4 binding site [12,14]. The ob-
served modest variations in adjacent surface-accessible
residues in gp120 of some primary isolates (i.e., Pro 369,
Thr 373, and Lys 432) could account for reduced recogni-
tion by CD4 binding site antibodies. In addition, many of
the residues that line the cavity interact with elements of the
chemokine receptor-binding region. It may be that the Phe
43 cavity and the other interdomain cavities form as a
consequence of a CD4-induced conformational change
(CD4i). It is important to emphasize that the above studieswere conducted with gp120 (SU) that lacked several vari-
able loops (i.e., V1/V2, V3). Therefore, additional interac-
tions between residues in these loops and the coreceptors
most likely play critical roles. However, they may not be
deciphered by crystallization studies.3. Coreceptor/gp120 interactions
AN extensive effort has been taken to map the regions
and specific amino acids in CCR5 and CXCR4 that interact
with gp120. Both CD4-dependent and CD4-independent
interactions have been analyzed (Table 1). The main con-
clusions drawn to date are: (A) All the Cys residues are
important for appropriate coreceptor function; most likely
they are involved in disulfide bonds. (B) The N-terminal
and second extracellular domain (ECII) of the coreceptors
seems to be most crucial for gp120 binding and fusion.
However, different strains interact with these regions differ-
ently and were affected to various degrees by site-directed
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coreceptor glycosylation is controversial. Unlike with CD4,
deglycosylated CXCR4 and CCR5 are expressed normally
and function as coreceptors. Furthermore, deglycosylated
CXCR4 demonstrated expanded tropism, supporting bind-
ing and fusion of dual tropic and several R5 viruses [15,16].
(D) There are conserved elements in both CXCR4 and
CCR5 that are involved in coreceptor function [17–19].
(E) Other posttranslational modifications of the HIV cor-
eceptors further modulate their function by changing their
surface density and by directly affecting the affinity of
gp120/coreceptor interactions or coreceptor/CD4 associa-
tion (see below).
The exact role played by the coreceptors in triggering the
conformational changes in the envelope transmembrane
protein (gp41) to facilitate membrane fusion has not been
deciphered. The current model of HIV entry proposes a
substantial refolding and stepwise transition of gp41 from a
metastable, native conformation through a pre-hairpin fu-
sion intermediate to a thermostable, six-helix bundle struc-
ture that brings the two membranes together and results in
fusion pore formation [20,21]. The six-helix bundle is
created when two heptad repeat motifs (HR) in the ectodo-
main of gp41 self-assemble into a trimer of hairpins. The
gp120 binding to cellular receptors ‘‘loosens’’ its association
with gp41, probably resulting in the release of the hydro-
phobic fusion peptide at the N terminus of gp41 from a
sequestered site so that it can insert into the target mem-
brane. With the fusion peptide inserted into the target
membrane and the transmembrane region embedded in the
viral membrane, gp41 is likely to fold into the compact six-
helix bundle, which is the most stable form, and its
formation is associated with energy release [22]. Peptides
mimicking the N-HR and C-HR were shown to capture
gp41 fusion-active pre-hairpin intermediates [23]. Unex-
pectedly, CD4 alone was required and was sufficient to
induce C–HR or N–HR peptide binding to gp41 [24].
However, peptide binding was clearly enhanced when Env
was activated by both CD4 and coreceptors [25]. Therefore,
the main role played by coreceptors may be to increase the
overall avidity of viral-cell binding and to increase the
number of spikes undergoing conformational changes be-
yond a threshold that is required to overcome the energy
barrier, resulting in fusion pore formation and membrane
mergence.4. Coreceptor/CD4 interactions
In early studies in cell lines, the recruitment of corecep-
tors into trimolecular complexes on the surface of target
cells depended on the initial binding of gp120 to its primary
receptor, CD4 [26,27]. However, in the promocytic cell line
U937, a low level co-precipitation of CD4 and CXCR4 was
observed in the absence of soluble gp120, suggesting some
constitutive association between CD4 and coreceptors [26].Subsequently, several studies in primary cells demonstrated
significant levels of preexisting CD4–coreceptor complexes
that can be co-precipitated from monocytes, macrophages,
thymocytes, and to a lesser degree from circulating T cells
(Ref. [28–31], and M. Zaitseva, in preparation). These
associations may occur in specialized membrane micro-
domains. They are influenced by the relative densities of
CD4 and coreceptors in different cell types, and the avidity
of CCR5/CD4 interactions may be stronger than that of
CXCR4/CD4 [30]. Furthermore, we demonstrated that the
coreceptor competition for association with CD4 may
change the susceptibility of human cells to infection with
X4- and R5- HIV-1 isolates, and should be taken into
consideration when designing clinical trials of coreceptor-
targeted inhibitors [32]. In addition, recent publication
provides evidence for CD4-enhanced signaling through
chemokine receptor CCR5, suggesting a functional outcome
of such interactions [33].5. Role of posttranslational modifications of coreceptors
in HIV-1-mediated cell fusion
Several factors besides densities of CD4 and coreceptors
may influence the efficiency of interactions between the
HIV-1 envelope proteins and cellular receptors, and lead to
viral entry. CCR5 and CXCR4 may be expressed in multiple
conformations that are recognized differentially by anti-
coreceptor antibodies [34,35]. Such heterogeneity may
influence the ability of coreceptors to support viral entry
and may explain cell-type specific differences in suscepti-
bility to infection [36]. CXCR4 and CCR5 are members of
the seven-transmembrane domain receptor family. As such,
their function could be affected by receptor dimerization
[37], by the membrane microenvironment, and by posttrans-
lational modifications of the coreceptors.
Posttranslational modifications of CXCR4 and CCR5
include modifications of the extracellular domains (N ter-
minal, ECI, ECII, and ECIII) or the intracellular loops.
Modifications of the extracellular domains include N-linked
and O-linked glycosylation and tyrosine sulfation. The
intracellular loops of the coreceptors may undergo palmi-
toylation, phosphorylation, and ubiquitination. These three
types of modifications play a major role in receptor turnover
and will be discussed in relation to receptor endocytosis and
recycling.
The carbohydrate moieties expressed by glycoproteins are
important for stability, intracellular trafficking, expression on
the cell surface, and for protein folding. Glycosylation sites
are present at the N-terminal sequences of the majority of
seven-transmembrane domain receptors. CXCR4 contains
two potential sites for N-linked glycosylation in the N
terminus and ECII loop [38]. Removal of carbohydrate
moieties by endoglycosidase F digestion induced a 10-kDa
shift in CXCR4 mobility in SDS-PAGE, suggesting that one,
or perhaps both, potential N-linked glycosylation sites in
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sylation sites by site-directed mutagenesis did not diminish
coreceptor function but rather expanded its ability to be used
by several HIV-1 isolates that normally use only CCR5 [15].
The authors of the study speculated that different glycoforms
of CXCR4 may exist in vivo, and that at the early stages of
the infection, R5 isolates could infect target cells via non-
glycosylated form of CXCR4 [17].
Unlike CXCR4, CCR5 has only one site for potential N-
linked glycosylation, but it is not used [39]. Instead, Ser 6
and Ser 7 at the N terminus of CCR5 are modified by O-
linked glycosylation in cell lines and in primary macro-
phages [40]. Importantly, the absence of O-glycans on
CCR5 had minimal effect on the efficiency of HIV-1 or
SIV entry, but their absence prevented binding of the CCR5
ligands MIP-1 a and MIP-1h [40].
Tyrosine sulfation is a posttranslational modification
common to many secreted and membrane-bound proteins.
It plays an important role in protein–protein interactions that
enhance leukocyte adhesion. A tyrosine-rich region, a po-
tential site for tyrosine sulfation, is present at the N-terminal
regions of several coreceptors, including CCR5 and CXCR4
[41]. Prevention of tyrosine sulfation substantially decreased
HIV-1 entry without affecting CCR5 expression [40,41].
Based on the critical role of tyrosine sulfation in viral entry,
a new peptide inhibitor that mimics the sulfated region of
CCR5 was generated and was shown to successfully block
R5 virus entry in vitro [42]. All studies on sulfation of
tyrosine residues in CCR5 and CXCR4 have been performed
using cell lines transfected with coreceptor genes. Therefore,
it is still not clear whether susceptibility and/or specificity of
primary cells to HIV-1 entry is attenuated by the presence or
absence of sulfated moieties. The enzyme tyrosyl protein
sulfotransferase (TPST) generates this modification in the
Golgi compartment, and it is not known whether the activity
of TPST enzymes is cell-type-specific or could be altered
under physiological conditions, thus contributing to hetero-
geneity of coreceptor sulfation and function.
In summary, glycosylation and sulfation of the extracel-
lular coreceptor domains may contribute to the efficacy and
specificity of fusion by providing larger binding interface
and by increasing the overall negative charge, facilitating
the electrostatic interactions with gp120.6. The role of coreceptor internalization and recycling in
fusion
Multiple studies with mutated and truncated forms of
CXCR4 and CCR5 demonstrated that coreceptor internali-
zation is not required for HIV entry. However, the rate of
receptor internalization and recycling can control its surface
density and fusion potential. In addition, the protective
effect of therapeutic agents targeting the HIV coreceptors
depends not only on their ability to bind but also to deplete
coreceptor molecules from the cell surface [43–45].The classical pathway of GPCR internalization is medi-
ated by agonist-induced endocytosis via clathrin-coated pits.
Endocytosis is promoted by a highly conserved mechanism
mediated by h-arrestin (reviewed in Refs. [46–48]). It is
thought that following endocytosis, GPCRs can be targeted
to two different pathways: receptors may recycle back to the
cell membrane or directed to lysosomes for degradation
(reviewed in Ref. [49]). Much of the current knowledge on
GPCRs internalization was derived from studies on h2-
adrenergic and g-opioid receptors. Determination of the
mechanisms underlying trafficking and internalization of
CXCR4 and CCR5 has only recently begun. In the absence
of ligand, the level of surface coreceptor expression is
determined by a balance between the rate of internalization
and the rate of replacement (recycling or new synthesis).
CXCR4 and CCR5 undergo significant spontaneous endo-
cytosis followed by recycling to the cell surface [50,51].
Spontaneous internalization of CXCR4 leads to its redistri-
bution from the membrane to the endocytic compartment
but not to lysosomes for degradation [50]. In addition, large
intracellular stores of CXCR4 were found in various leuko-
cyte subsets [52]. Following physiological stimuli or cell
culture, the intracellular pool of CXCR4 was shown by us
[53] and by others [54] to translocate to the cell surface.
Nonspontaneous internalization of coreceptors can be in-
duced by specific agonists (chemokines) or by chemokine
analogues, and, in T cells, by strong cell activation. Specific
agonists induce internalization of both CXCR4 and CCR5,
while only CXCR4 undergoes internalization in response to
phorbol-ester [51,52,55–57].
Following SDF-1-induced receptor internalization, a sig-
nificant proportion of CXCR4 is translocated to the lyso-
somes and is targeted to the degradative pathway [58] with
only a small proportion of CXCR4 being recycled back to
the cell surface depending on the cell type [50]. At the same
time, CCR5 agonists induce its redistribution to endosomal
vesicles followed by recycling to the cell surface [51]; so far
there have been no reports indicating that CCR5 is subject to
lysosome-dependent degradation.
Rapid phosphorylation of serine residues within the
cytoplasmic tails of many GPCR including CXCR4 and
CCR5 is an essential step in receptor internalization follow-
ing ligand binding [56,59–61]. Phosphorylation of serine
residues can be mediated by GPCR kinases (GRK) or by
protein kinase C (PKC) [62,63]. Importantly, phosphoryla-
tion of serine residues in CCR5 is kinase-specific: Ser 337 is
exclusively phosphorylated by a PKC-mediated process,
while GRK phosphorylates Ser 349 (see below) [63].
Phosphorylated serine residues in the C terminus of CCR5
provide a binding site for h-arrestin, an intracellular adaptor
molecule that facilitates endocytosis, [61]. h-arrestin was
also shown to associate physically with phosphorylated
CXCR4 [64]. Two distinct sites for h-arrestin binding were
detected within CXCR4, one in the third intracellular loop
and one at the C terminus [65]. However, while binding of
h-arrestin to the third intracellular domain promotes recep-
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CXCR4 interferes with receptor coupling to G proteins [65].
Recently, it has been shown that in GPCR signaling, h-
arrestins perform an additional function as scaffold proteins
by recruiting components of MAPK cascade and thus
coupling GPCR to down-stream G-protein-independent sig-
naling events, including activation of ERK1/2 and JNK/
SAPK [66]. Additional mechanisms may provide fine-
tuning of phosphorylation. For example, phosphorylation
of the serine residues at the C terminus of CCR5 was shown
to be dependent on the presence of palmitoylated cysteine
residues [61,67]. It was suggested that this lipid modifica-
tion may attenuate the activity of GRK by controlling the
access to serine residues within the C terminus of CCR5
[61].
Down modulation of CXCR4 can be induced by SDF-1
and phorbol esters and is mediated through either one of two
internalization signals: the serine-rich domain and Ser/IleLeu
(di-leucine) motif within the cytoplasmic tail of CXCR4
[55,56]. Lack of di-leucine motif in CCR5 may explain the
inability of phorbol esters to induce CCR5 internalization
[62]. This motif was previously shown to function as
endocytosis signal in CD4 and in the g-subunit of the TCR
complex, and is believed to promote interaction with AP2
clathrin adaptor complex [68–70]. It was suggested that
CXCR4, unlike CCR5, has a capacity to interact with two
distinct sets of endocytic adaptors, the AP2 complex and h-
arrestins. Both of these interactions are likely to be regulated
through phosphorylation of distinct sets of serine residues
within its cytoplasmic tail [56]. As discussed earlier, inter-
nalization of CXCR4 occurs in response to either phorbol
ester treatment or SDF-1 binding and is mediated via
clathrin-coated vesicles. However, CXCR4 was reported to
recycle back to the cell surface after phorbol-ester removal
and to enter degradative pathway after activation with SDF-1
[50,55]. Therefore, it is reasonable to suggest that selective
engagement of the adaptor molecules may determine the fate
of endocytosed CXCR4—degradation or recycling.
The ubiquitin/proteasome system and lysosomes are
two major intracellular machineries responsible for protein
turnover. In cell lines, proteasome inhibitors reduced
CXCR4 internalization, thus implicating a role for the
ubiquitination machinery in the trafficking of CXCR4
[71]. However, in other experimental systems, CXCR4
degradation was sensitive to lysosomotrophic but not
proteasomic inhibitors [58]. In addition, rapid ubiquitina-
tion of the cytoplasmic tail of CXCR4 was shown to occur
upon agonist treatment, and this modification was sug-
gested to serve as a sorting signal for lysosome-mediated
degradation of surface CXCR4 [58]. Three lysine residues,
potential sites for ubiquitin binding, are located next to a
di-leucine motif within the SSLKILSKGK degradation
signal in the cytoplasmic tail of CXCR4. Based on studies
of CXCR4 mutants, it was suggested that agonist-induced
phosphorylation of serine residues within the degradation
motif enables binding of ubiquitin molecules to neighbor-ing lysine residues, and this association promotes interac-
tion with yet unknown adaptor molecules that sort CXCR4
for lysosomal degradation [58]. Studies from our labora-
tory suggested that ubiquitination might contribute to the
observed heterogeneity of CXCR4 species detected in
human primary cells [31]. Our data further suggest that
even in the absence of SDF-1 binding, ubiquitination of
CXCR4 plays a role in intracellular trafficking of fusion-
competent isoforms of CXCR4 and may induce conforma-
tional changes favoring the association of CXCR4 with
CD4 in primary cells (Ref. [31] and M. Zaitseva, unpub-
lished observations). Furthermore, CXCR4 turnover may
be controlled not only by ubiquitination of the receptor
itself but also by the ubiquitination status of associated
adaptor molecules, as was demonstrated recently for h2-
adrenergic receptors [72].
According to a widely accepted model, dephosphoryla-
tion of a GPCR within the acidic milieu of the endosomal
vesicle is a crucial step for subsequent recycling to the cell
surface [73]. Two phosphatases, SHP2 and SHIP, have been
reported to associate with CXCR4 constitutively and upon
activation [74,75] and therefore may be possible candidates
for dephosphorylation of endocytosed CXCR4. However,
recent data demonstrated that, in some cases, dephosphor-
ylation of GPCR does not require trafficking of the receptor
to endosomes. Importantly, it was shown that at low
concentration of the agonist, CCR5 is phosphorylated by
PKC and then is rapidly dephosphorylated at the plasma
membrane by an unknown GPCR phosphatase (GRP) that is
active at neutral pH and therefore differs from the endo-
some-associated GRP [63]. The rapid endosome-indepen-
dent dephosphorylation of CCR5 was suggested to provide
a mechanism to maintain cell-membrane receptors in a non-
phosphorylated and therefore signaling-competent status
[63].7. Coreceptor-targeted therapies: modified chemokines,
small molecule inhibitors, and intrakines
Chemokine receptors constitute an important target for
the development of anti-HIV-1 therapies. As stated above,
the ability of CC chemokines to block HIV-1 infection was
one of the factors that implicated chemokine receptors as
coreceptors for HIV-1 [4]. The main mechanism of antiviral
activity of chemokines is based on chemokine-induced
internalization of chemokine receptors into early endosomes
[43,44,51]. On the other hand, inefficient internalization of
CCR5 in macrophages and transfected adherent cell lines
correlated with low HIV-1 inhibitory activity by chemokine
analogues in these cells [45].
Infusion of native chemokines in vivo as therapeutic
agents to control viral spread is compromised by a short
half-life (less than 10 min) and their potential proinflamma-
tory effects [76]. Therefore, novel strategies have been
employed to overcome these limitations [77]. They include
M. Zaitseva et al. / Biochimica et Biophysica Acta 1614 (2003) 51–6156but are not limited to modified chemokines, small molecules
that target chemokine receptors, intrakines, and monoclonal
antibodies.
7.1. Modified chemokines
The major goal in designing modified forms of chemo-
kines is to create coreceptor antagonists that interact with
the receptor with high enough affinity to prevent HIV-1
entry by blocking relevant epitopes and/or inducing cor-
eceptor down modulation. At the same time, it is important
that these antagonists are incapable of inducing signaling.
In search for chemokine antagonists that can satisfy these
criteria, RANTES, MIP-1a, and SDF-1 were subjected to
chemical modifications or were truncated. Several deriva-
tives of RANTES that bind to CCR5 and inhibit infection
of lymphocytes and cells of the macrophage lineage with
R5 viruses were identified: truncated forms of RANTES
that lack two or six N-terminal residues, RANTES(3–68)
and RANTES(9–68) [78,79], and a derivative of RANTES
that was created by chemical modification of the amino-
terminus, aminooxypenetene (AOP)-RANTES [80]. All
three modified molecules were shown to induce less
chemotaxis than intact RANTES. However, their anti-
HIV effects differed, with RANTES(9–68) being less
effective and AOP-RANTES and RANTES(3–68) being
more potent in blocking infection with R5 viruses than
unmodified RANTES [78,80]. In addition, several recom-
binant analogues of RANTES with substitution of selected
residues in the N-terminal region were generated [81].
C1.C5-RANTES and L-RANTES showed a dramatically
reduced ability to trigger intracellular calcium mobilization
while exhibiting an increased antiviral activity against R5
primary isolates, suggesting that minor alterations of
RANTES at the N terminus play a major role in deter-
mining chemotactic and antiviral activity and that the
antiviral and signaling functions of RANTES can be
uncoupled [81]. To further improve RANTES-based ago-
nists, the fusion protein between RANTES and human
IgG3 (RANTES-IgG3) was generated [82]. Even though
RANTES-IgG3 was no more effective than intact
RANTES in inhibiting of HIV infection, the authors
pointed out certain desirable properties that were provided
by this product: IgG fusion proteins have extended half-
lives in vivo and molecules with IgG heavy chain moieties
may be able to cross the placenta and potentially induce
fetal protection [82,83]. Two MIP-1a derivatives with
potent CCR5 antagonist activity were recently described.
AOP-MIP-1a was shown to be about 10-fold more active
than AOP-RANTES at inhibiting HIV entry [84]. LD78-a,
an isoform that differs from MIP-1a only in three amino
acids, is more potent in preventing viral entry than native
MIP-1 a and RANTES. However, unlike AOP-MIP-1 a,
LD78- a induces signaling [84,85]. In addition to modified
agonists of CCR5, truncated form of the plasmatic human
CC chemokine 1, HCC-1(9–74), displayed potent antiviralactivities by inducing down-regulation of CCR5 on pri-
mary cells [86]. However, the effect of HCC-1(9–74) on
viral replication was donor-cell-dependent, sensitive to
HIV-1 isolate variations [87].
Some attempts have been made to generate an optimized
CXCR4 antagonist. Addition of an N-terminal methionine
residue to SDF-1 a resulted in increased antiviral activity
[88]. However, the long-term effects of Met-SDF-1 a on
infection are unknown and could be compromised by its
enhanced signaling activity [88].
Chemokine analogues exert their antiviral inhibitory
activities primarily by inducing internalization of chemo-
kine receptors [44,51,84,87]. Both RANTES and AOP-
RANTES induced down modulation of cell surface CCR5
and its targeting to early endosomes [44,51]. However, only
AOP-RANTES prevented CCR5 recycling to the cell sur-
face [44], resulting in a more long-lasting depletion of
coreceptors. In addition, AOP-RANTES showed reduced
capacity to induce chemotactic responses. The ability to
induce effective internalization of CCR5, coupled with
reduced proinflammatory signaling, makes AOP-RANTES
an attractive candidate for development as antiviral therapy.
However, it should be noted that RANTES and RANTES
analogues were shown to enhance the infectivity of HIV-1
in vitro in some systems, possibly due to chemokine-
induced cell activation [87,89,90]. In addition, N-nona-
noyl-RANTES (NNY-RANTES) was shown with the 242
R5 virus to select for coreceptor switch to CXCR4-using
viral variants in vivo in the hu-PBL-SCID mouse system
[91]. Therefore, it may be important to develop a strategy
that could prevent rapid selection of viruses with alternative
coreceptor usage by simultaneously targeting CCR5 and
CXCR4 coreceptors [92].
Future design of therapies based on chemokine ana-
logues may be confounded by several factors: (A) there is
a large degree of variability in the sensitivity of primary
isolates to chemokine-mediated inhibition [93]; (B) chemo-
kine binding is augmented by surface proteoglycan mole-
cules, which vary among cell types [94]; and (C) down
modulation of CCR5 may free surface CD4 molecules for
association with CXCR4, making the cells more susceptible
to infection with cytopathic X4 viruses [32].
7.2. Small molecule antagonists of coreceptor function
Small molecule antagonists of coreceptor function rep-
resent a recently emerging group of antiviral drugs that are
designed to interfere with the initial stages of viral enve-
lope binding to the cell membrane. The primary mecha-
nism of their antiviral activity does not rely on down
modulation of the coreceptors but seems to be due to
receptor occupancy. The advantage of small molecule-
based inhibitors is that they are unlikely to induce signal-
ing and therefore to indirectly augment viral entry or to
induce inflammation. Several important small molecules
have been described so far. A small-molecule CCR5
Table 2
Summary of activity of small molecules that inhibit HIV entry
Inhibitor Coreceptor Ligand
activity
Chemical Active
concentrationa
SDF-1 CXCR4 Ligand Chemokine 0.2–5 mg/ml;
30 nM
Met-SDF-1 CXCR4 Antagonist Mod.
Chemokine
1.0–2.8 mg/ml
AMD-3100 CXCR4 Antagonist Bicyclam 2–7 ng/ml;
20 nM
KRH-1636 CXCR4 Antagonist LMW 18–152 nM
ALX40-4C CXCR4 Antagonist Peptide
(9 aa)
3–20 nM
T22 CXCR4 Antagonist Peptide
(18 aa)
5–290 nM
T140 CXCR4 Antagonist Peptide
(14 aa)
0.18–12 nM
T134 CXCR4 Antagonist Peptide
(14 aa)
2–74 nM
RANTES CCR5 Ligand Chemokine 61 nM;
480 ng/ml
AOP-
RANTES
CCR5 Antagonist Mod.
Chemokine
0.3–3 nM
NYY-
RANTES
CCR5 Antagonist Mod.
Chemokine
40–300 nM
TAK-779 CCR5 Antagonist LMWb 10–100 nM
SCH-351125
(SCH-C)
CCR5 Antagonist Oxime-
piperidine
2.3–13.4 nM
SCH-350581
(AD101)
CCR5 Antagonist Oxime-
piperidine
0.3–1.5 nM
T20 Fusion NRc Peptide 0.07–0.31
Ag/ml;
2–40 nM
a Values are ranges and depend on the assay, cells, and viruses used.
b Low molecular weight compound.
c NR, not relevant.
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virus replication with laboratory-adapted and clinical iso-
lates without any cytotoxicity to the host cells [95]. It was
further shown that TAK-779 inhibits HIV-1 replication at
the membrane-fusion stage and that the binding pocket for
TAK-779 on CCR5 is located near the extracellular surface
of the receptor within a cavity formed between transmem-
brane helices 1, 2, 3, and 7 [96]. Another candidate for
blocking CCR5/envelope interactions is SCH-C [97]. This
oxime-piperidine compound specifically inhibited infec-
tions with R5 HIV-1 in in vitro cell cultures and in vivo
in SCID mice reconstituted with human thymic tissue.
Importantly, SCH-C has a serum half-life of 5–6 h, which
makes it a good candidate for the development of antiviral
therapies [97].
Several small molecules demonstrated potent inhibitory
activity against the coreceptor function of CXCR4. The
bicyclam AMD3100 efficiently blocks cell/cell fusion and
HIV-1 entry of both X4 and X4R5 viruses by binding to
a conserved region of CXCR4 [98,99]. Importantly, even
though AMD3100 prevents SDF-1 from binding to its
receptor, AMD3100 by itself does not cause signaling
[98]. It has been suggested that AMD3100 induces
conformational alterations of the receptor [100]. The
results obtained with AMD3100 compound are reminis-
cent of those generated with a cationic peptide derived
from a horseshoe crab blood cells, T22 ({Tyr5,12, Lys7}-
polyphemusin II) [101]. T22 was shown to inhibit repli-
cation of both laboratory-adapted and primary isolates of
HIV-1 by binding to the N terminus and to two extra-
cellular loops of CXCR4 [101,102]. Importantly, T22 did
not induce signaling or CXCR4 down modulation at the
concentrations required for inhibition of infection (200
nM) and was shown to interfere with very early events of
viral/cell or cell/cell fusion at the stage of lipid mixing
[102]. AMD3100 and T22 both inhibit the binding of the
CXCR4-specific antibody 12G5 and of SDF-1 to CXCR4
[103]. However, recently it was shown that T134, a T22
derivative, efficiently inhibits replication of an
AMD3100-resistant HIV-1 isolate, therefore suggesting
that the sites of AMD3100 and of T22 activity on
CXCR4 only partially overlap [104]. Further development
of T22-based therapies will result in synthesis of T22
analogues that exhibit reduced cytotoxic effect on the
host cells and at the same time preserve high anti-HIV
activity [105].
The molecular mechanisms underlying the high-affinity
binding of small molecules to coreceptors have not been
investigated in detail. Small molecules can inhibit by
steric hindrance to prevent interaction of gp120 with
the receptor, or by inducing a global conformation
change unfavorable to coreceptor function. In this regard,
some light have been shed on the activity of the CXCR4
antagonist ALX40-4C. It was shown that the binding site
of ALX40-4C partially overlaps with that of 12G5 and
SDF-1 [106]. Importantly, it was further demonstratedthat successful binding of SDF-1 and of ALX40-4C to
CXCR4 is critically dependent on positively charged
residues present in the synthetic peptide inhibitor as well
as the beta-sheet region of SDF-1 [107]. The important
role of electrostatic interactions between coreceptor and
inhibitor was further demonstrated for AMD3100, in
which interactions between positively charged residues
(analogous to the highly basic V3 loop of the gp120 in
X4 viruses) and negatively charged amino acid residues
located in transmembrane domains 4, 6 and 7 of CXCR4
[103] were demonstrated.
One of the problems with the small molecule coreceptor
inhibitors described to date if they were to move into the
clinic is that they cannot be taken orally and must be
injected. A recent description of KRH-1636, an antagonist
of CXCR4 that blocks infection of primary cells by
primary and laboratory-adapted X4 viruses with similar
efficiencies to those of AMD3100 but that is absorbed
through the duodenum, would have an advantage for clini-
cal use [108].
In summary, a progress has been achieved in the devel-
opment of antiviral therapies based on small molecule
antagonists of coreceptors. It is important to note, however,
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mutant variants during long-term passage in the presence of
a CCR5-specific small molecule inhibitor [109]. Interest-
ingly, the escape mutant was not able to use CXCR4 or any
other tested coreceptor and was still dependent on low levels
of CCR5, suggesting that newly emerged virus was able to
use a drug-bound form of the receptor [109]. The properties
of some of the small molecule inhibitors are summarized in
Table 2.
7.3. Intrakines
One of the recently developed strategies designed to
inhibit binding of the viral envelope to the cell surface is
based on the trapping of the chemokine receptor in the
cytoplasm by the intracellular expression of chemokines
engineered to contain an endoplasmic reticulum (ER) reten-
tion signal [110,111]. Such ‘‘intrakines’’ have been prepared
with SDF-1 and RANTES, and their genes are transduced
into PBMC using retroviral vectors. Intrakines function by
binding to the newly synthesized chemokine receptors and
trap them in the ER. PBMC transduced with SDF-1- or with
RANTES-based intrakines are resistant to infection with X4
or R5 viruses, respectively, but these cells retained their
basic biological functions [110–112]. Antiviral therapies
that involve intrakines may have potential for inactivating
CCR5 safely, since homozygous inactivation of this receptor
has not been associated with loss of immune function
[113,114]. In contrast, CXCR4 is broadly expressed in cells
of both the immune and the central nervous systems (CNS),
and both SDF-1 and CXCR4 were shown to play an
essential role in hematopoiesis, in cerebral development in
mice [115,116], and in thymocyte development in humans
[117]. In addition, intrakine-transduced adult mice exhibited
impaired lymphopoiesis and myelopoiesis [118], suggesting
that in vivo inactivation of CXCR4 by intrakines may not be
safe.
7.4. Anti-coreceptors monoclonal antibodies (mAb)
Several CCR5-specific mAb were described with very
potent anti viral activity in vitro [34,119,120]. However,
their further development as in vivo therapies will be
confounded by the development of anti-mouse IgG response
and the potential selection of virus variants with altered
tropism. Nevertheless, under conditions of short-term treat-
ment such as child birth, coreceptor-specific mAbs may be
used as part of inhibitor-cocktail to block mother to child
intrapartum transmission.
7.5. New microbial-derived coreceptor inhibitors
Recently, it was found that cyclophilin C-18 from the
parasite Toxoplasma gondii binds specifically to CCR5
[121]. Importantly, C-18 was found to block binding of
R5 HIV-1 envelope and to inhibit R5 virus infection ofactivated PBMC without CCR5 down modulation (H. Gold-
ing, submitted for publication). Studies will test the suit-
ability of this microbial-derived protein as a coreceptor
antagonist in vivo.References
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